The study randomized 61 patients into three treatment groups (two dose levels of Topical PTH (1-34) and one vehicle only group) for an eight-week treatment period at four US clinical trial sites. The vehicle used in this study is the topical product without the active ingredient, PTH (1-34). The company expects to announce the results of this study in summer 2008.
Douglas Abel, president and CEO of Manhattan Pharmaceuticals, said: “We are pleased to have completed enrollment in this Phase IIa study on schedule. We look forward to completing the study and announcing results later this year.”